{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:54:38Z","timestamp":1777290878476,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.bone.2018.12.012","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T02:35:12Z","timestamp":1545014112000},"page":"482-486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7427-9361","authenticated-orcid":false,"given":"Sophie","family":"Roux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Massicotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Huot Daneault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Brazeau-Lamontagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Dufresne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bone.2018.12.012_bb0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.2000.15.1.2","article-title":"The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption","volume":"15","author":"Hofbauer","year":"2000","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2018.12.012_bb0010","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2018.12.012_bb0015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2018.12.012_bb0020","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","article-title":"Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update","volume":"36","author":"Anderson","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.bone.2018.12.012_bb0025","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bone.2018.12.012_bb0030","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s00198-016-3535-5","article-title":"Hypercalcemia after discontinuation of long-term denosumab treatment","volume":"27","author":"Koldkj\u00e6r S\u00f8lling","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"10","key":"10.1016\/j.bone.2018.12.012_bb0035","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood-2018-06-856740","article-title":"Multiple subperiosteal bone resorption in adult T-cell leukemia\/lymphoma","volume":"132","author":"Katsuragi","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bone.2018.12.012_bb0040","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1056\/NEJMicm1308814","article-title":"Images in clinical medicine. Subperiosteal bone resorption","volume":"370","author":"Taguchi","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bone.2018.12.012_bb0045","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1210\/en.2014-1046","article-title":"Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes","volume":"155","author":"Ben-awadh","year":"2014","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.bone.2018.12.012_bb0050","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1210\/jc.2007-1645","article-title":"The role of the receptor activator of nuclear factor-kappaB ligand\/osteoprotegerin cytokine system in primary hyperparathyroidism","volume":"93","author":"Nakchbandi","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2018.12.012_bb0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bone.2018.12.012_bb0060","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/jbmr.2112","article-title":"Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice","volume":"29","author":"Rinotas","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2018.12.012_bb0065","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/pbc.25393","article-title":"Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone","volume":"62","author":"Gossai","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.bone.2018.12.012_bb0070","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","article-title":"Severe hypercalcemia following denosumab treatment in a juvenile patient","volume":"34","author":"Setsu","year":"2016","journal-title":"J. Bone Miner. Metab."},{"issue":"2","key":"10.1016\/j.bone.2018.12.012_bb0075","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1210\/jc.2017-02025","article-title":"Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone","volume":"103","author":"Uday","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bone.2018.12.012_bb0080","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1210\/jc.2013-1143","article-title":"Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease","volume":"98","author":"Grasemann","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.bone.2018.12.012_bb0085","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2018.12.012_bb0090","first-page":"76","article-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","volume":"18","author":"Trejo","year":"2018","journal-title":"J. Musculoskelet. Neuronal Interact."},{"issue":"2","key":"10.1016\/j.bone.2018.12.012_bb0095","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1309\/BPET-F2PE-P2BD-J3P3","article-title":"RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone","volume":"117","author":"Roux","year":"2002","journal-title":"Am. J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.bone.2018.12.012_bb0100","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJMoa013096","article-title":"Osteoprotegerin deficiency and juvenile Paget's disease","volume":"347","author":"Whyte","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2018.12.012_bb0105","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/ar2171","article-title":"Clinical development of anti-RANKL therapy","volume":"9","author":"Schwarz","year":"2007","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.bone.2018.12.012_bb0110","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bcp.12355","article-title":"The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review","volume":"78","author":"Sohn","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.bone.2018.12.012_bb0115","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1210\/endo.139.11.6433","article-title":"Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells","volume":"139","author":"Horwood","year":"1998","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.bone.2018.12.012_bb0120","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/jbmr.89","article-title":"Function of OPG as a traffic regulator for RANKL is crucial for controlled osteoclastogenesis","volume":"25","author":"Aoki","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2018.12.012_bb0125","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.biocel.2006.11.008","article-title":"RANK ligand","volume":"39","author":"Blair","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"4","key":"10.1016\/j.bone.2018.12.012_bb0130","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.bone.2006.03.016","article-title":"OPG\/membranous\u2013RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation","volume":"39","author":"Tat","year":"2006","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2018.12.012_bb0135","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bbrc.2004.11.076","article-title":"Modulation of osteoclast formation","volume":"328","author":"Quinn","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bone.2018.12.012_bb0140","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1124\/jpet.108.137703","article-title":"Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients","volume":"326","author":"Marathe","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bone.2018.12.012_bb0145","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","article-title":"Adverse effects of bisphosphonates. A comparative review","volume":"14","author":"Adami","year":"1996","journal-title":"Drug Saf."},{"issue":"9","key":"10.1016\/j.bone.2018.12.012_bb0150","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1359\/JBMR.050522","article-title":"Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases","volume":"20","author":"Cremers","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2018.12.012_bb0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328218304629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328218304629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T15:32:19Z","timestamp":1548862339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328218304629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":31,"alternative-id":["S8756328218304629"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2018.12.012","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2018.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}